PRELAJ, ARSELA
 Distribuzione geografica
Continente #
NA - Nord America 2.432
AS - Asia 1.824
EU - Europa 1.598
SA - Sud America 383
AF - Africa 57
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.297
Nazione #
US - Stati Uniti d'America 2.382
RU - Federazione Russa 688
SG - Singapore 552
CN - Cina 471
IT - Italia 425
BR - Brasile 321
VN - Vietnam 260
KR - Corea 137
HK - Hong Kong 95
DE - Germania 83
FI - Finlandia 75
JP - Giappone 75
FR - Francia 69
BD - Bangladesh 63
NL - Olanda 63
GB - Regno Unito 45
IN - India 34
AT - Austria 32
ID - Indonesia 32
CA - Canada 29
IE - Irlanda 26
AR - Argentina 21
CI - Costa d'Avorio 14
ES - Italia 14
PH - Filippine 14
SE - Svezia 14
EC - Ecuador 13
IQ - Iraq 13
PL - Polonia 11
TR - Turchia 10
MX - Messico 9
UA - Ucraina 9
ZA - Sudafrica 9
DK - Danimarca 8
SA - Arabia Saudita 8
AZ - Azerbaigian 7
BE - Belgio 7
CO - Colombia 7
PK - Pakistan 7
TH - Thailandia 7
UZ - Uzbekistan 7
KG - Kirghizistan 6
MA - Marocco 6
BJ - Benin 5
CH - Svizzera 5
KE - Kenya 5
PY - Paraguay 5
TW - Taiwan 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 4
UY - Uruguay 4
BO - Bolivia 3
EG - Egitto 3
IL - Israele 3
JM - Giamaica 3
NG - Nigeria 3
PT - Portogallo 3
SN - Senegal 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
CL - Cile 2
DO - Repubblica Dominicana 2
EE - Estonia 2
HN - Honduras 2
HR - Croazia 2
JO - Giordania 2
KZ - Kazakistan 2
LB - Libano 2
NO - Norvegia 2
NP - Nepal 2
RS - Serbia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
CV - Capo Verde 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GF - Guiana Francese 1
GT - Guatemala 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
LT - Lituania 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MM - Myanmar 1
MU - Mauritius 1
NA - Namibia 1
PE - Perù 1
PF - Polinesia Francese 1
RO - Romania 1
Totale 6.297
Città #
Ashburn 456
Singapore 345
San Jose 269
Chandler 187
Santa Clara 148
Seoul 131
Council Bluffs 127
Hefei 115
Fairfield 105
Moscow 95
Boardman 90
Hong Kong 89
The Dalles 88
Milan 86
Beijing 77
Ho Chi Minh City 71
Tokyo 64
Helsinki 59
Hanoi 53
Houston 47
Los Angeles 46
Lauterbourg 43
Seattle 42
Cambridge 41
Wilmington 33
Rome 31
Woodbridge 31
Amsterdam 29
New York 27
North Charleston 27
São Paulo 27
Dublin 26
Vienna 26
Lawrence 23
Munich 23
Dallas 22
San Diego 20
Frisco 18
Kent 17
Redmond 17
Ann Arbor 16
Buffalo 16
Dong Ket 16
Frankfurt am Main 15
Jakarta 14
Abidjan 13
Nuremberg 13
Princeton 13
Medford 12
Rio de Janeiro 12
Toronto 12
Haiphong 11
Las Vegas 11
Palermo 11
Atlanta 10
Da Nang 10
Redwood City 10
Salt Lake City 10
Lappeenranta 9
London 9
Salvador 9
Chicago 8
Madrid 8
Manila 8
Orem 8
Warsaw 8
Baku 7
Changsha 7
Johannesburg 7
Stockholm 7
Tashkent 7
Turin 7
Turku 7
Bishkek 6
Chūō 6
Curitiba 6
Philadelphia 6
Porto Alegre 6
Americana 5
Bari 5
Brasília 5
Brooklyn 5
Brussels 5
Chennai 5
Copenhagen 5
Cotonou 5
Düsseldorf 5
Goiânia 5
Guangzhou 5
Guayaquil 5
Hangzhou 5
Naples 5
Poplar 5
Tianjin 5
Zhengzhou 5
Belo Horizonte 4
Bergamo 4
Campinas 4
Can Tho 4
Caravaggio 4
Totale 3.747
Nome #
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients 248
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review 244
Abstract PO-065: Artificial intelligence to improve selection for NSCLC patients treated with immunotherapy 230
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 181
Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort 180
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy 175
Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records 174
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non–Small-Cell Lung Cancer: An External Validation 174
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? 166
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out 165
Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis 162
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer 161
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis 152
178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients 149
MetaLung: Towards a Secure Architecture for Lung Cancer Patient Care on the Metaverse 149
Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma 147
Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression 142
Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation 140
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 139
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy 138
The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project 134
Gastrointestinal stromal tumors and second primary malignancies: a retrospective monocentric analysis 132
Exploring the role of respiratory microbiome in lung cancer: A systematic review 130
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy 130
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system 128
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors 124
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis 123
An ensemble approach to predict immunotherapy efficacy in non-small cell lung cancer using digital pathology 120
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer 118
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study 114
Immunotherapy beyond progression in patients with advanced non-small cell lung cancer 113
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy 112
Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients 105
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 103
Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease 101
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program 100
Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development 99
Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib 95
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors 94
Novel emerging molecular targets in non-small cell lung cancer 92
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 91
SMO mutations confer poor prognosis in malignant pleural mesothelioma 88
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma 87
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations 83
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake 79
Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of EGFR-mutated advanced NSCLC patients 49
Integrating radiomics and real-world data to predict immune checkpoint inhibitor efficacy in advanced non-small-cell lung cancer 35
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer 33
Trustworthy assessment of 2D model for lung CT scans 25
A Contrastive Variational AutoEncoder for NSCLC Survival Prediction with Missing Modalities 23
Aiding data retrieval in clinical trials with large language models: The APOLLO 11 Consortium in advanced lung cancer patients 23
Automatic Cough Analysis for Non-Small Cell Lung Cancer Detection 18
Predicting efficacy in patients with locally advanced/metastatic urothelial carcinoma (mUC) treated with immunotherapy using explainable machine learning approaches: the SamUR-AI trial on behalf of the Meet-URO group 14
Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours 13
Cost-effectiveness models of non–small cell lung cancer: A systematic literature review 8
Totale 6.352
Categoria #
all - tutte 20.067
article - articoli 18.891
book - libri 0
conference - conferenze 1.176
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.134


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202150 0 0 0 0 0 0 0 0 0 0 0 50
2021/2022267 34 27 26 11 11 27 7 17 11 12 40 44
2022/2023362 40 49 10 45 48 32 4 27 58 21 20 8
2023/2024280 13 29 12 14 11 20 7 28 29 21 19 77
2024/2025917 32 19 29 40 145 88 29 73 115 56 129 162
2025/20264.077 593 678 228 334 241 165 562 258 304 417 147 150
Totale 6.352